StoneX Group Inc. Has $4.07 Million Stake in Amgen Inc. (NASDAQ:AMGN)

StoneX Group Inc. reduced its holdings in Amgen Inc. (NASDAQ:AMGN) by 6.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,624 shares of the medical research company’s stock after selling 914 shares during the period. StoneX Group Inc.’s holdings in Amgen were worth $4,068,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Capital Performance Advisors LLP bought a new position in shares of Amgen in the 3rd quarter worth $25,000. Hershey Financial Advisers LLC bought a new position in Amgen during the second quarter worth about $30,000. nVerses Capital LLC bought a new position in Amgen during the second quarter worth about $31,000. Bbjs Financial Advisors LLC acquired a new position in shares of Amgen during the 2nd quarter worth about $33,000. Finally, Matrix Trust Co bought a new stake in shares of Amgen in the 3rd quarter valued at about $36,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

AMGN opened at $294.53 on Friday. The business’s 50-day simple moving average is $316.52 and its 200 day simple moving average is $318.11. Amgen Inc. has a 52-week low of $260.68 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The firm has a market capitalization of $158.32 billion, a PE ratio of 37.71, a PEG ratio of 2.59 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter in the prior year, the business posted $4.96 EPS. The business’s revenue was up 23.2% compared to the same quarter last year. As a group, sell-side analysts expect that Amgen Inc. will post 19.52 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date is Monday, November 18th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Analyst Ratings Changes

AMGN has been the subject of a number of analyst reports. StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Wells Fargo & Company lowered shares of Amgen from an “overweight” rating to an “equal weight” rating and boosted their price target for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Citigroup initiated coverage on Amgen in a report on Thursday, November 14th. They set a “neutral” rating and a $335.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $362.00 price target on shares of Amgen in a research report on Thursday, September 26th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $380.00 price objective on shares of Amgen in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $333.57.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.